Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Genmab plans to present full results at an upcoming medical meeting.

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states. The methods of subtyping diffuse large B-cell lymphoma (DLBCL) have changed over ...

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

The trial enrolled around 900 adults aged 18 to 80 years.

The authors say their 3D model improves on results using traditional 2-dimensional approaches. A new report suggests a microfluid platform could be a meaningful tool to screen potential new therapies ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We are so lucky in DLBCL to make more rapid ...

ORLANDO, Florida — New results suggest that radiotherapy can be skipped by some patients with diffuse large B-cell lymphoma (DLBCL). But the new results suggest that patients with an interim positron ...